Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features

Anna Enjuanes, Robert Albero, Guillem Clot, Alba Navarro, Sílvia Beà, Magda Pinyol, José I. Martín-Subero, Wolfram Klapper, Louis M. Staudt, Elaine S. Jaffe, Lisa Rimsza, Rita M. Braziel, Jan Delabie, James R. Cook, Raymond R. Tubbs, Randy Gascoyne, Joseph M. Connors, Dennis D. Weisenburger, Timothy C. Greiner, Wing Chung ChanArmando Lõpez-Guillermo, Andreas Rosenwald, German Ott, Elías Campo, Pedro Jares

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Mantle cell lymphoma (MCL) is a B-cell neoplasm with an aggressive clinical behavior characterized by the t(11;14)(q13;q32) and cyclin D1 overexpression. To clarify the potential contribution of altered DNA methylation in the development and/or progression of MCL, we performed genome-wide methylation profiling of a large cohort of primary MCL tumors (n = 132), MCL cell lines (n = 6) and normal lymphoid tissue samples (n = 31), using the Infinium HumanMethylation27 BeadChip. DNA methylation was compared to gene expression, chromosomal alterations and clinicopathological parameters. Primary MCL displayed a heterogeneous methylation pattern dominated by DNA hypomethylation when compared to normal lymphoid samples. A total of 454 hypermethylated and 875 hypomethylated genes were identified as differentially methylated in at least 10% of primary MCL. Annotation analysis of hypermethylated genes recognized WNT pathway inhibitors and several tumor suppressor genes as frequently methylated, and a substantial fraction of these genes (22%) showed a significant downregulation of their transcriptional levels. Furthermore, we identified a subset of tumors with extensive CpG methylation that had an increased proliferation signature, higher number of chromosomal alterations and poor prognosis. Our results suggest that a subset of MCL displays a dysregulation of DNA methylation characterized by the accumulation of CpG hypermethylation highly associated with increased proliferation that may influence the clinical behavior of the tumors.

Original languageEnglish (US)
Pages (from-to)2852-2863
Number of pages12
JournalInternational Journal of Cancer
Volume133
Issue number12
DOIs
StatePublished - Dec 15 2013

Keywords

  • genome-wide
  • hypermethylation
  • hypomethylation
  • mantle cell lymphoma
  • pathogenesis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features'. Together they form a unique fingerprint.

  • Cite this

    Enjuanes, A., Albero, R., Clot, G., Navarro, A., Beà, S., Pinyol, M., Martín-Subero, J. I., Klapper, W., Staudt, L. M., Jaffe, E. S., Rimsza, L., Braziel, R. M., Delabie, J., Cook, J. R., Tubbs, R. R., Gascoyne, R., Connors, J. M., Weisenburger, D. D., Greiner, T. C., ... Jares, P. (2013). Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. International Journal of Cancer, 133(12), 2852-2863. https://doi.org/10.1002/ijc.28321